這則官方新聞可能把美國新冠疫苗研發時間提前到2019年8月

連結：

https://www.curevac.com/news/curevac-enters-into-an-exclusive-collaborative-research-agreement-for-discovery-research-in-mrna-based-lung-therapy-candidates-with-yale-university

譯文：

CureVac與耶魯大學籤訂了一份獨家合作研究協議，對基於mRNA的肺治療候選藥物進行發現研究

2019年8月13日

電子郵件新聞稿

TÜBINGEN，德國/麻薩諸塞州波士頓，2019年8月13日-CureVac AG，一家開創基於mRNA藥物領域的完全整合的生物製藥公司，今天宣布，它已經與耶魯大學籤訂了一項合作研究協議（「CRA」），對基於mRNA的肺部治療候選疫苗進行發現研究。

獨家的CRA涵蓋了未知數量的新型基於mRNA的肺部疾病候選藥物的開發。根據CRA的條款，由Geoff Chupp醫學博士領導的耶魯大學團隊將對與肺部疾病相關的靶點進行發現性研究，並為臨床前和隨後的臨床發展提供治療vac的候選者。CureVac將為探索研究提供所有資金，並保留獲得候選人相關權利的選擇權。

耶魯大學合作研究辦公室商業發展主任約翰·普齊斯博士說：「我們很高興有機會與CureVac合作，共同研究我們希望成為下一代治療嚴重呼吸系統疾病的藥物。」。

Chupp博士補充道：「mRNA療法是藥物開發的前沿，CureVac是這一領域的領導者。我們非常高興有機會將我們在肺病基因組學方面的專業知識與CureVac在mRNA治療開發方面的專業知識結合起來，開發出新的肺病治療方法。我們期待著富有成果的合作。」

「我們很榮幸能與耶魯大學團隊合作，該團隊正在進行肺部領域的前沿發現研究，」CureVac執行長丹·梅尼切拉（Dan Menichella）說。「CureVac的下一代mRNA載體，CureVac載體分子™ （化學氣相色譜法™)，能達到肺等器官的靶點，非常適合反覆給藥。我們期待著發現耶魯大學潛在的新治療候選人，幫助為那些最需要醫療服務的人提供解決方案。」

關於CureVac AG

CureVac是信使RNA（mRNA）技術領域的領先公司，擁有超過19年的處理和優化醫用多功能分子的專業經驗。CureVac專有技術的原理是利用mRNA作為數據載體，指導人體產生自身能夠對抗多種疾病的蛋白質。公司將其技術應用於癌症治療、抗體治療、罕見疾病治療和預防性疫苗的開發。迄今為止，CureVac已獲得約4.2億美元（4億歐元）的股權投資，其中包括SAP創始人Dietmar Hopp的dievini和Bill&Melinda Gates基金會的重大投資。CureVac還與跨國公司和組織進行了合作，包括Boehringer Ingelheim、Eli Lilly&Co、CRISPR Therapeutics、Bill&Melinda Gates Foundation等。

2019年8月13日公司新聞截圖

---

原文：

CureVac Enters into an Exclusive Collaborative Research Agreement for Discovery Research in mRNA-based Lung Therapy Candidates with Yale University

08-13-2019

Email Press Release

TÜBINGEN, Germany / BOSTON, MA, August 13, 2019 – CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced today it has entered into a Collaborative Research Agreement (「CRA」) with Yale University for discovery research into mRNA-based pulmonary therapeutic candidates.

The exclusive CRA covers the development of an undisclosed number of novel mRNA-based candidates for pulmonary diseases. Under terms of the CRA, the Yale University team, led by Geoff Chupp, MD, will perform discovery research on targets related to pulmonary diseases and present therapeutic candidates to CureVac for preclinical and subsequent clinical development. CureVac will provide all funding for the discovery research and retains the option to acquire any rights regarding the candidates.

「We’re delighted to have the opportunity to partner with CureVac to work on what we hope will be the next generation of therapeutics for patients with severe respiratory disease,」 said John Puziss, PhD, the Director of Business Development in Yale’s Office of Cooperative Research.

Dr. Chupp added, 「mRNA therapeutics are at the forefront of drug development and CureVac is a leader in the field. We are very excited about the opportunity to merge our expertise in genomics of lung disease with CureVac’s expertise in mRNA therapeutic development to develop novel therapeutics for lung disease. We look forward to a fruitful collaboration.」

「We are honored to partner with the Yale team, which is performing cutting edge discovery research in the pulmonary field,」 said Dan Menichella, CEO of CureVac. 「CureVac’s next generation mRNA delivery vehicle, the CureVac Carrier Molecule™ (CVCM™), can reach targets in the lung and other organs and is well suited for repeated administration. We look forward to uncovering potential new therapeutic candidates with Yale University to help provide solutions to those with the greatest medical need.」

About CureVac AG

CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 19 years』 expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. To date, CureVac has received approximately $420 million (€400 million) in equity investments, including significant investments from SAP founder Dietmar Hopp’s dievini and the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, CRISPR Therapeutics, the Bill & Melinda Gates Foundation, and others.